Therapeutic-dose efzofitimod reduced sarcoidosis relapse rates
A study shows therapeutic doses of Atyr Pharma’s experimental therapy efzofitimod were associated with a lower rate of relapse in people with pulmonary sarcoidosis who were tapering oral corticosteroids, a mainstay treatment linked with toxic side effects when given for long periods and at high doses. While the…